Monoclonal antibodies to the soluble antigens or cell surface markers hold great promise as effective human therapeutics. One of the major disadvantages is its large size, which prevents efficient penetration into the target tissues. Smaller version of antibodies, which has only antigen binding sites, is extensively investigated. It becomes increasingly apparent, however, that these smaller fragments of antibodies are rather difficult to produce, as the normally efficient mammalian secretion system does not work well for these fragments. Thus, refolding of insoluble proteins produced in Escherichia coli is a method of choice, although such refolding is mainly based on trial-and-error experiment. Here we describe a novel refolding system using a new amino acid-based detergent, N-lauroyl-L-glutamate, and arginine. This detergent appears to readily dissociate from proteins below critical micelle concentration (CMC), while remaining effective in protein solubilization above CMC. Arginine suppresses protein aggregation when the detergent concentration was reduced below CMC. The interaction of the detergent and arginine with proteins, which play an important role in protein refolding, will be discussed in great length.
References
[1]
Yamada, T. Therapeutic monoclonal antibodies. Keio J. Med. 2011, 60, 37–46, doi:10.2302/kjm.60.37.
[2]
Jenkins, N.; Meleady, P.; Tyther, R.; Murphy, L. Strategies for analysing and improving the expression and quality of recombinant proteins made in mammalian cells. Biotechnol. Appl. Biochem. 2009, 53, 18–25.
[3]
Shukla, A.A.; Thommes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253–261, doi:10.1016/j.tibtech.2010.02.001.
[4]
Shukla, A.A.; Hubbard, B.; Tressel, T.; Guhan, S.; Low, D. Downstream processing of monoclonal antibodies-application of platform approaches. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848, 28–39, doi:10.1016/j.jchromb.2006.09.026.
[5]
Low, D.; O’Leary, R.; Pujar, N.S. Future of antibody purification. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848, 48–63, doi:10.1016/j.jchromb.2006.10.033.
[6]
Chon, J.H.; Zarbis-Papastoitsis, G. Advances in the production and downstream processing of antibodies. N. Biotechnol. 2011, 28, 458–463.
[7]
Beck, A.; Wurch, T.; Bailly, C.; Corvaia, N. Challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10, 345–352, doi:10.1038/nri2747.
[8]
Demarest, S.J.; Glaser, S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Dev. 2008, 11, 675–687.
Moffat, F.L.J.; Gulec, S.A.; Serafini, A.N.; Sfakianakis, G.N.; Pop, R.; Robinson, D.S.; Franceschi, D.; Boggs, J.; Livingstone, A.S. A thousand points of light and just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. Cancer Invest. 1999, 17, 322–334, doi:10.3109/07357909909032874.
[11]
Colcher, D.; Goel, A.; Pavlinkova, G.; Beresford, G.; Booth, B.; Batra, S.K. Effects of genetic engineering on the pharmacokinetics of antibodies. Q. J. Nucl. Med. 1999, 43, 132–139.
[12]
Nelson, A.L.; Reichert, J.M. Development trends for therapeutic antibody fragments. N. Biotechnol. 2009, 27, 331–337.
[13]
Yazaki, P.J.; Shively, L.; Clark, C.; Cheung, C.-W.; Le, W.; Szpikowska, B.; Shively, J.E.; Raubitschek, A.A.; Wu, A.M. Mammalian expression and hollow fiber biorector production of recombinant anti-CEA diabody and minibody for clinical applications. J. Immunol. Methods 2001, 253, 195–208, doi:10.1016/S0022-1759(01)00388-X.
[14]
Accardi, L.; Di Bonito, P. Antibodies in single-chain format against tumour-associated antigens: Present and future applications. Curr. Med. Chem. 2010, 17, 1730–1755, doi:10.2174/092986710791111215.
[15]
W？rn, A.; Plückthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 2001, 305, 989–1010, doi:10.1006/jmbi.2000.4265.
[16]
Stockwin, L.H.; Holmes, S. The role of therapeutic antibodies in drug discovery. Biochem. Soc. Trans. 2003, 31, 433–436, doi:10.1042/BST0310433.
[17]
Liu, Y.; Liu, Y.; Mernaugh, R.L.; Zeng, X. Single chain fragment variable recombinant antibody functionalized gold nanoparticles for a highly sensitive colorimetric immunoassay. Biosens. Bioelectron. 2009, 24, 2853–2867, doi:10.1016/j.bios.2009.02.016.
[18]
Schmidt, S.R. Fusion-proteins as biopharmaceuticals-applications and challenges. Curr. Opin. Drug Discov. Dev. 2009, 12, 284–295.
[19]
Makabe, K.; Asano, R.; Ito, T.; Tsumoto, K.; Kudo, T.; Kumagai, I. Tumorpdirected lymphocyte-activating cytokines: Refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis. Biochem. Biophys. Res. Commun. 2005, 328, 98–105, doi:10.1016/j.bbrc.2004.12.141.
[20]
Sharkey, R.M.; Goldenberg, D.M. Perspective on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 2005, 46, 115S–127S.
[21]
Kelly, M.P.; Lee, F.T.; Tahtis, K.; Power, B.E.; Smyth, F.E.; Brechbiel, M.W.; Hudson, P.J.; Scott, A.M. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y Antibody construct. Cancer Biother. Radiopharm. 2008, 23, 411–423, doi:10.1089/cbr.2007.0450.
[22]
Beckman, R.A.; Weiner, L.M.; Davis, H.M. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 2007, 109, 170–179, doi:10.1002/cncr.22402.
[23]
Ottiger, M.; Thiel, M.A.; Feige, U.; Lichtlen, P.; Urech, D.M. Efficient intracocular penetration of topical anti-TNF-α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest. Ophthal. Vis. Sci. 2009, 50, 779–786.
[24]
Wittel, U.A.; Jain, M.; Goel, A.; Chauhan, S.C.; Colcher, D.; Batra, S.K. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl. Med. Biol. 2005, 32, 157–164, doi:10.1016/j.nucmedbio.2004.11.003.
[25]
Kirschning, C.J.; Dreher, S.; Maass, B.; Fichte, S.; Schade, J.; K？ster, M.; Noack, A.; Lindenmaier, W.; Wagner, H.; B？ldicke, T. Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation. BMC Biotechnol. 2010, 10, 31, doi:10.1186/1472-6750-10-31.
[26]
Xiong, H.; Li, S.; Yang, Z.; Burgess, R.R.; Dynan, W.S. E. coli expression of a soluble, active single-chain antibody variable fragment containing a nuclear localization signal. Protein Expr. Purif. 2009, 66, 172–180, doi:10.1016/j.pep.2009.03.002.
[27]
Poul, M.A. Selection of antibodies able to rapidly enter mammalian cells. Methods Mol. Biol. 2009, 562, 155–163, doi:10.1007/978-1-60327-302-2_12.
[28]
Butler, D.C.; McLear, J.A.; Messer, A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog. Neurobiol. 2012, 97, 190–204, doi:10.1016/j.pneurobio.2011.11.004.
[29]
Hasegawa, H.; Wendling, J.; He, F.; Trilisky, E.; Stevenson, R.; Franey, H.; Kinderman, F.; Li, G.; Piedmonte, D.M.; Oslund, T.; Shen, M.; Ketchem, R.R. In vivo crystallization of human IgG in the endoplasmic reticulum of engineered CHO cell. J. Biol. Chem. 2011, 286, 19917–19931.
[30]
Wurm, F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. N. Biotechnol. 2004, 22, 1393–1398, doi:10.1038/nbt1026.
[31]
Humphreys, D.P.; Glover, D.J. Therapeutic antibody production technologies: Molecules, applications, expression and purification. Curr. Opin. Drug Dev. 2001, 4, 172–185.
[32]
Andersen, D.C.; Reilly, D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15, 456–462, doi:10.1016/j.copbio.2004.08.002.
[33]
Arbabi-Ghahroudi, M.; Tanha, J.; MacKenzie, R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005, 24, 501–519, doi:10.1007/s10555-005-6193-1.
[34]
Sun, W.; Xie, J.; Lin, H.; Mi, S.; Li, Z.; Hua, F.; Hu, Z. A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies. Protein Expr. Purif. 2012, 83, 21–29, doi:10.1016/j.pep.2012.02.006.
[35]
Lilie, H.; Schwarz, E.; Rudolph, R. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol. 1998, 9, 497–501, doi:10.1016/S0958-1669(98)80035-9.
[36]
Tsumoto, K.; Ejima, D.; Kumagai, I.; Arakawa, T. Practical consideration in refolding proteins from inclusion bodies. Protein Expr. Purif. 2003, 28, 1–8, doi:10.1016/S1046-5928(02)00641-1.
[37]
Zardeneta, G.; Horowits, P.M. Detergent, liposome, and micelle-assisted protein refolding. Anal. Biochem. 1994, 223, 1–6, doi:10.1006/abio.1994.1537.
[38]
Zardeneta, G.; Horowitz, P.M. Protein refolding at high concentrations using detergent/phospholipid mixtures. Anal. Biochem. 1994, 218, 392–398, doi:10.1006/abio.1994.1197.
[39]
Michaux, C.; Pomroy, N.C.; Priv？, G.G. Refolding SDS-denatured proteins by the addition of amphipathic cosolvents. J. Mol. Biol. 2008, 375, 1477–1488, doi:10.1016/j.jmb.2007.11.026.
[40]
Lu, H.; Clogston, C.L.; Narhi, L.O.; Merewether, L.A.; Pearl, W.R.; Boone, T.C. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J. Biol. Chem. 1992, 267, 8770–8777.
[41]
Kurucz, I.; Titus, J.A.; Jost, C.R.; Segal, D.M. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol. Immunol. 1995, 32, 1443–1452, doi:10.1016/0161-5890(95)00105-0.
[42]
Fursova, K.K.; Laman, A.G.; Melnik, B.S.; Semisotnov, G.V.; Kopylov, P.K.; Kiseleva, N.V.; Nesmeyanov, V.A.; Brovko, F.A. Refolding of scFv mini-antibodies using size-exclusion chromatography via arginine solution layer. J. Chromatogr. B 2009, 877, 2045–2051, doi:10.1016/j.jchromb.2009.05.038.
[43]
Tsumoto, K.; Shinoki, K.; Kondo, H.; Uchikawa, M.; Juji, T.; Kumagai, I. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagents-application to a human single-chain Fv fragment. J. Immunol. Methods 1998, 219, 119–129, doi:10.1016/S0022-1759(98)00127-6.
[44]
Fujii, T.; Ohkuri, T.; Onodera, R.; Ueda, T. Stable supply of large amounts of human Fab from the inclusion bodies in E. coli. J. Biochem. 2007, 141, 699–707, doi:10.1093/jb/mvm075.
[45]
Kudou, M.; Yumioka, R.; Ejima, D.; Arakawa, T. A novel protein refolding system using lauroyl-L-glutamate as a solubilizing detergent and arginine as a folding assisting agent. Protein Expr. Purif. 2011, 75, 46–54, doi:10.1016/j.pep.2010.08.011.
[46]
Kudou, M.; Ejima, D.; Sato, H.; Yumioka, R.; Arakawa, T. Refolding single-chain antibody (scFv) using lauroyl-L-glutamate as a solubization detergent and arginine as a refolding additive. Protein Expr. Purif. 2011, 7, 68–74.
[47]
Xia, J.; Nnanna, I.A.; Sakamoto, K. Amino acid surfactants: Chemistry, synthesis, and properties. In Protein-Based Surfactants. Synthesis, Physicochemical Properties, and Applications; Nnanna, I.A., Xia, J., Eds.; Marcel Dekker: New York, NY, USA, 2001; pp. 75–122.
[48]
Ejima, D.; Watanabe, M.; Sato, Y.; Date, M.; Yamada, N.; Takahara, Y. High yield refolding and purification process for recombinant interleukin-6 expressed in Escherichia coli. Biotechnol. Bioeng. 1999, 62, 301–310, doi:10.1002/(SICI)1097-0290(19990205)62:3<301::AID-BIT6>3.0.CO;2-W.
[49]
Boone, T.; Chazin, V.; Kenney, W.; Swanson, E.; Altrock, B. Construction, purification and biological activities of recombinant human interleukin-2 analogs. Dev. Biol. Stand. 1988, 69, 157–168.
[50]
Umetsu, M.; Tsumoto, K.; Hara, M.; Ashish, K.; Goda, S.; Adshiri, T.; Kumagai, I. How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J. Biol. Chem. 2003, 278, 8979–8987.
[51]
Reddy, K.R.C.; Lilie, H.; Rudolph, R.; Lange, C. L-Arginine increases the solubility of unfolded species of hen egg white lysozyme. Protein Sci. 2005, 14, 929–935, doi:10.1110/ps.041085005.
[52]
Armstrong, N.; de Lencastre, A.; Gouaux, E. A new protein folding screen: Application to the ligand binding domains of a glutamate and kainite receptor and to lysozyme and carbonic anhydrase. Protein Sci. 1999, 8, 1475–1483, doi:10.1110/ps.8.7.1475.
[53]
Oneda, H.; Inouye, K. Refolding and recovery of recombinant human matrix metalloproteinase (matrilysin) from inclusion bodies expressed by Escherichia coli. J. Biochem. 1999, 126, 905–911, doi:10.1093/oxfordjournals.jbchem.a022533.
[54]
Arora, D.; Khanna, N. Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J. Biotechnol. 1996, 52, 127–133.
[55]
Suenaga, M.; Ohmae, H.; Tsuji, S.; Itoh, T.; Nishimura, O. Renaturation of recombinant human neurotrophin-3 from inclusion bodies using a suppressor agent of aggregation. Biotechnol. Appl. Biochem. 1998, 28, 119–124.
[56]
Rattenholl, A.; Ruoppolo, M.; Flagiello, A.; Monti, M.; Vinci, F.; Marino, G.; Lilie, H.; Schwarz, E.; Rudolph, R. Pro-sequence assisted folding and disulfide bond formation of human nerve growth factor. J. Mol. Biol. 2001, 305, 523–533, doi:10.1006/jmbi.2000.4295.
[57]
Asano, R.; Kudo, T.; Makabe, K.; Tsumoto, K.; Kumagai, I. Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett. 2002, 528, 70–76, doi:10.1016/S0014-5793(02)03254-4.
[58]
Bajorunaite, E.; Sereikaite, J.; Bumelis, V. L-arginine suppresses aggregation of recombinant growth hormones in refolding process from E. coli inclusion bodies. Protein J. 2007, 26, 547–555, doi:10.1007/s10930-007-9096-x.
[59]
Takahashi, S.; Ogasawara, H.; Watanabe, T.; Kumagai, M.; Inoue, H.; Hori, K. Refolding and activation of human prorenin expressed in Escherichia coli: Application of recombinant human renin for inhibitor screening. Biosci. Biotechnol. Biochem. 2006, 70, 2913–2918, doi:10.1271/bbb.60334.
[60]
Lechtken, A.; Zundorf, I.; Dingermann, T.; Firla, B.; Steinhiber, D. Overexpression, refolding, and purification of polyhistidine-tagged human retinoic acid related orphan receptor RORalpha4. Protein Expr. Purif. 2006, 49, 114–120, doi:10.1016/j.pep.2006.03.012.
[61]
Hsih, M.H.; Kuo, J.C.; Tsai, H.J. Optimization of the solubilization and renaturation of fish growth hormone produced by Escherichia coli. Appl. Microbiol. Biotechnol. 1997, 48, 66–72, doi:10.1007/s002530051016.
[62]
Wang, X.T.; Engel, P.C. An optimized system for refolding of human glucose 6-phosphate dehydrogenase. BMC Biotechnol. 2009, 9, 19–29, doi:10.1186/1472-6750-9-19.
[63]
Rudolph, R.; Opitz, U.; Hesse, F.; Riebland, R.; Fischer, S. Reactivation of microbially produced human tissue-type plasminogen activator. In Biotechnology International; North, K., Ed.; Century Press Ltd.: London, UK, 1992; pp. 321–325.
[64]
Rinas, U.; Risse, B.; Jaenicke, R.; Abel, K.J.; Zettlmeissl, G. Denaturation-renaturation of the fibrin-stabilizing factor XIII a-chain isolated from human placenta: Properties of the native and reconstituted protein. J. Biol. Chem. 1990, 371, 49–56.
[65]
Ahn, J.H.; Lee, Y.P.; Rhee, J.S. Investigation of refolding condition for Pseudomonas fluorescence lipase by response methodology. J. Biotech. 1997, 54, 151–160.
[66]
Yancey, P.H.; Clark, M.E.; Hand, S.C.; Bowlus, R.D.; Somero, G.N. Living with water stress: Evolution of osmolyte systems. Science 1982, 217, 1214–1222.
[67]
Ishibashi, M.; Tsumoto, K.; Ejima, D.; Arakawa, T.; Tokunaga, M. Charatcerization of arginine as a solvent additive: A halophilic enzyme as a model protein. Protein Pept. Lett. 2005, 12, 649–653, doi:10.2174/0929866054696136.
[68]
Rudolph, R.; Fisher, S. Process for obtaining renatured proteins. US patent 4,933,434, 12 June 1990.
[69]
Tischer, A.; Lilie, H.; Rudolph, R.; Lange, C. L-Arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA. Protein Sci. 2010, 19, 1783–1795, doi:10.1002/pro.465.
[70]
Lange, C.; Rudolph, R. Suppression of protein aggregation by L-arginine. Curr. Pharm. Biotechnol. 2009, 10, 408–414, doi:10.2174/138920109788488851.
[71]
Yokoyama, K.; Kunio, O.; Ohtsuka, T.; Nakamura, N.; Seguro, K.; Ejima, D. In vitro refolding process of urea-denatured microbial transgltaminase without pro-peptide sequence. Protein Expr. Purif. 2002, 26, 329–335, doi:10.1016/S1046-5928(02)00536-3.
[72]
Hirai, A.; Tanaka, S.; Kawasaki, H.; Nemoto, N.; Suzuki, M.; Maeda, H. Effects of arginine on aggregates of fatty-acid/potassium soap in the aqueous media. Colloid Polym. Sci. 2006, 284, 520–528, doi:10.1007/s00396-005-1423-1.
[73]
Nozaki, Y.; Tanford, C. The solubility of amino acids and related compounds in aqueous ethylene glycol solutions. J. Biol. Chem. 1965, 240, 3568–3575.
[74]
Nozaki, Y.; Tanford, C. The solubility of amino acids and related compounds in aqueous urea solutions. J. Biol. Chem. 1963, 238, 4074–4081.
[75]
Nozaki, Y.; Tanford, C. The solubility of amino acids, diglycine, and triglycine in aqueous guanidine hydrochloride solutions. J. Biol. Chem. 1970, 245, 1648–1652.
[76]
Nozaki, Y.; Tanford, C. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. J. Biol. Chem. 1971, 246, 2211–2217.
[77]
Gekko, K. Calorimetric study on thermal denaturation of lysozyme in polyol-water mixtures. J. Biochem. 1982, 91, 1197–1204.
[78]
Gekko, K.; Koga, S. Increased thermal stability of collagen in the presence of sugars and polyols. J. Biochem. 1983, 94, 199–205.
[79]
Liu, Y.; Bolen, D.W. The peptide backbone plays a dominant role in protein stabilization by naturally occurring osmolytes. Biochemistry 1995, 34, 12884–12891, doi:10.1021/bi00039a051.
[80]
Arakawa, T.; Kita, Y.; Timasheff, S.N. Protein precipitation and denaturation by dimethyl sulfoxide. Biophys. Chem. 2007, 131, 62–70, doi:10.1016/j.bpc.2007.09.004.
[81]
Arakawa, T.; Timasheff, S.N. Mechanism of protein salting in and salting out by divalent cation salts: Balance between hydration and salt binding. Biochemistry 1984, 23, 5912–5923, doi:10.1021/bi00320a004.
[82]
Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S.N. Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects. Biophys. Chem. 2007, 127, 1–8, doi:10.1016/j.bpc.2006.12.007.
[83]
Tanford, C. Contribution of hydrophobic interactions to the stability of the globular conformation of proteins. J. Am. Chem. Soc. 1962, 84, 4240–4247, doi:10.1021/ja00881a009.
[84]
Dioguardi, F.S. To give or not to give. J. Nutrigenet. Nutrigenomics 2011, 4, 90–98, doi:10.1159/000327777.
[85]
Maity, H.; Karkaria, C.; Davagino, J. Mapping of solution components, pH changes, protein stability and the elimination of protein precipitation during freeze-thawing of fibroblast growth factor 20. Int. J. Pharm. 2009, 378, 122–135, doi:10.1016/j.ijpharm.2009.05.063.
[86]
Maity, H.; Karkaria, C.; Davagnino, J. Effects of pH and arginine on the solubility and stability of a therapeutic protein (Fibroblast Growth Factor 20): Relationship between solubility and stability. Curr. Pharm. Biotechnol. 2009, 10, 609–625, doi:10.2174/138920109789069297.
[87]
Ejima, D.; Yumioka, R.; Arakawa, T.; Tsumoto, K. Arginine as an effective additive in gel permeation chromatography. J. Chromatogr. A 2005, 1094, 49–55, doi:10.1016/j.chroma.2005.07.086.
[88]
Arakawa, T.; Tsumoto, K.; Nagase, K.; Ejima, D. The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography. Protein Expr. Purif. 2007, 54, 110–116, doi:10.1016/j.pep.2007.02.010.
[89]
Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Arakawa, T. Solubilization of active green fluorescent protein from inclusion particles by guanidine and arginine. Biochem. Biophys. Res. Commun. 2003, 312, 1383–1386, doi:10.1016/j.bbrc.2003.11.055.
[90]
Umetsu, M.; Tsumoto, K.; Nitta, S.; Adschiri, T.; Ejima, D.; Arakawa, T.; Kumagai, I. Nondenaturing solubilization of beta2 microglobulin from inclusion bodies by L-arginine. Biochem. Biophys. Res. Commun. 2005, 328, 189–197, doi:10.1016/j.bbrc.2004.12.156.
[91]
Yamasaki, H.; Tsujimoto, K.; Koyama, A.H.; Ejima, D.; Arakawa, T. Arginine facilitates inactivation of enveloped viruses. J. Pharm. Sci. 2008, 97, 3063–3073.
[92]
Katsuyama, Y.; Yamasaki, H.; Tsujimoto, K.; Koyama, A.H.; Ejima, D.; Arakawa, T. Butyroyl-arginine as a potent virus inactivation agent. Int. J. Pharm. 2008, 361, 92–98, doi:10.1016/j.ijpharm.2008.05.020.
[93]
Utsunimoya, H.; Ichinose, M.; Tsujimoto, K.; Katsuyama, Y.; Yamasaki, H.; Koyama, A.H.; Ejima, D.; Arakawa, T. Co-operative thermal inactivation of herpes simplex virus and influenza virus by arginine ans NaCl. Int. J. Pharm. 2009, 366, 99–102, doi:10.1016/j.ijpharm.2008.09.012.
[94]
Arakawa, T.; Kita, Y.; Koyama, A.H. Synergistic virus inactivation effects of arginine. Biotechnol. J. 2009, 4, 174–178.
[95]
Tsujimoto, K.; Uozaki, M.; Ikeda, K.; Yamazaki, H.; Utsunomiya, H.; Ichinose, M.; Koyama, A.H.; Arakawa, T. Solvent-induced virus inactivation by acidic arginine solution. Int. J. Mol. Med. 2010, 25, 433–437.
[96]
Naito, T.; Irie, H.; Tsujimoto, K.; Ikeda, K.; Arakawa, T.; Koyama, A.H. Antiviral effect of arginine against herpes simplex virus type 1. Int. J. Mol. Med. 2009, 23, 495–499.
[97]
Ohtake, S.; Arakawa, T.; Koyama, A.H. Arginine as a synergistic agent. Molecules 2010, 15, 1408–424, doi:10.3390/molecules15031408.
[98]
Nishide, M.; Tsujimoto, K.; Uozaki, M.; Ikeda, K.; Yamasaki, H.; Koyama, A.H.; Arakawa, T. Effects of electrolytes on virus inactivation by acidic solutions. Int. J. Mol. Med. 2011, 27, 803–809.
[99]
Ikeda, K.; Yamasaki, H.; Minami, S.; Naito, T.; Irie, H.; Arakawa, T.; Koyama, A.H. Virucidal ability of arginine and its possible application as an antiherpetic agent. In From the Hallowed Halls of Herpesvirology; Baines, J., Blaho, J., Eds.; Imperial College Press: London, UK, 2012; Chapter 18, pp. 435–450.
[100]
Hirano, A.; Kameda, T.; Arakawa, T.; Shiraki, K. Arginine-assisted solubilization system for drug substances: Solubility experiment and simulation. J. Phys. Chem. B 2010, 114, 13455–13462, doi:10.1021/jp101909a.
[101]
Arakawa, T.; Kita, Y.; Koyama, A.H. Solubility enhancement of gluten and coumarin by arginine. Int. J. Pharm. 2008, 355, 220–223, doi:10.1016/j.ijpharm.2007.12.009.
[102]
Hirano, A.; Arakawa, T.; Shiraki, K. Arginine increases the solubility of coumarin: Comparison with salting-in and salting-out additives. J. Biochem. 2008, 144, 363–369, doi:10.1093/jb/mvn078.
[103]
Arakawa, T.; Uozaki, M.; Koyama, A.H. Modulation of small molecule solubility and protein binding by arginine. Mol. Med. Rep. 2010, 3, 833–836.
[104]
Gekko, K.; Morikawa, T. Preferential hydration of bovine serum albumin in polyhydric alcohol-water mixtures. J. Biochem. 1981, 90, 39–50.
[105]
Lee, J.C.; Timasheff, S.N. The stabilization of proteins by sucrose. J. Biol. Chem. 1981, 256, 7193–7201.
[106]
Gekko, K.; Timasehff, S.N. Mechanism of protein stabilization by glycerol: Preferential hydration in glycerol-water mixtures. Biochemistry 1981, 20, 4667–4676, doi:10.1021/bi00519a023.
[107]
Arakawa, T.; Timasheff, S.N. Stabilization of protein structure by sugars. Biochemistry 1982, 21, 6536–6544, doi:10.1021/bi00268a033.
[108]
Arakawa, T.; Timasheff, S.N. Preferential interactions of proteins with salts in concentrated solutions. Biochemistry 1982, 21, 6545–6552, doi:10.1021/bi00268a034.
[109]
Kita, Y.; Arakawa, T.; Lin, T.Y.; Timasheff, S.N. Contribution of the surface free energy perturbation to protein-solvent interactions. Biochemistry 1994, 33, 15178–15189, doi:10.1021/bi00254a029.
[110]
Lee, J.C.; Timasheff, S.N. Partial specific volumes and interactions with solvent components in guanidine hydrochloride. Biochemistry 1974, 13, 257–265.
[111]
Prakash, V.; Loucheux, C.; Scheufele, S.; Borbunoff, M.J.; Timasheff, S.N. Interaction of proteins with solvent components in 8 M urea. Arch. Biochem. Biophys. 1981, 210, 455–464, doi:10.1016/0003-9861(81)90209-5.
[112]
Hong, J.; Capp, M.W.; Anderson, C.F.; Record, M.T. Preferential interactions in aqueous solution of urea and KCl. Biophys. Chem. 2003, 105, 517–532, doi:10.1016/S0301-4622(03)00112-1.
[113]
Timasheff, S.N.; Xie, G. Preferential interactions of urea with lysozyme and their linkage to protein denaturation. Biophys. Chem. 2003, 105, 421–448, doi:10.1016/S0301-4622(03)00106-6.
[114]
Bull, H.B.; Breese, K. Interaction of alcohols with proteins. Biopolymers 1978, 17, 2121–2131, doi:10.1002/bip.1978.360170907.
[115]
Inoue, H.; Timasheff, S.N. The interaction of beta-lactoglobulin with solvent components in mixed water-organic solvent systems. J. Am. Chem. Soc. 1968, 90, 1890–1898, doi:10.1021/ja01009a037.
[116]
Timasheff, S.N.; Inoue, H. Preferential binding of solvent components to proteins in mixed water-organic solvent systems. Biochemistry 1968, 7, 2501–2513, doi:10.1021/bi00847a009.
[117]
Inoue, H.; Timasheff, S.N. Preferential and absolute interactions of solvent components with proteins in mixed solvent systems. Biopolymers 1972, 11, 737–743, doi:10.1002/bip.1972.360110402.
[118]
Pittz, E.P.; Timasheff, S.N. Interaction of ribonuclease A with aqueous 2-methyl-2,4-pentanediol at pH 5.8. Biochemistry 1978, 17, 615–623, doi:10.1021/bi00597a009.
[119]
Arakawa, T.; Bhat, R.; Timasheff, S.N. Why preferential hydration does not always stabilize the native structure of globular proteins. Biochemistry 1990, 29, 1924–1931, doi:10.1021/bi00459a037.
[120]
Arakawa, T.; Timasheff, S.N. Preferential interactions of proteins with solvent components in aqueous amino acid solutions. Arch. Biochem. Biophys. 1983, 224, 169–177, doi:10.1016/0003-9861(83)90201-1.
[121]
Arakawa, T.; Timasheff, S.N. The mechanism of action of Na glutamate, lysine HCl, and piperazine-N,N′-bis(2-ethanesulfonic acid) in the stabilization of rubulin and microtuble formation. J. Biol. Chem. 1984, 259, 4979–4986.
[122]
Arakawa, T.; Timasheff, S.N. The stabilization of proteins by osmolytes. Biophys. J. 1985, 47, 411–414, doi:10.1016/S0006-3495(85)83932-1.
[123]
Arakawa, T.; Timasheff, S.N. Protein stabilization and destabilization by guanidinium salts. Biochemistry 1984, 23, 5923–5929.
[124]
Arakawa, T.; Timasheff, S.N. Theory of protein solubility. Methods Enzymol. 1985, 114, 49–77.
[125]
Arakawa, T.; Timasheff, S.N. Abnormal solubility behavior of beta-lactoglobulin: Salting-in by glycine and NaCl. Biochemistry 1987, 26, 5147–5153, doi:10.1021/bi00390a038.
Schneider, C.P.; Trout, B.L. Investigation of cosolute-protein preferential interaction coefficients: New insight into the mechanism by which arginine inhibits aggregation. J. Phys. Chem. 2009, 113, 2050–2058, doi:10.1021/jp808042w.
[128]
Ito, L.; Shiraki, K.; Matsuura, T.; Okumura, M.; Hasegawa, K.; Baba, S.; Yamaguchi, H.; Kumasaka, T. High-resolution X-ray analysis reveals binding of arginine to aromatic residues of lysozyme surface: Implication of suppression of protein aggregation by arginine. Protein Eng. Des. Sel. 2011, 24, 269–274, doi:10.1093/protein/gzq101.
[129]
Shukla, D.; Trout, B. Interaction of arginine with proteins and the mechanism by which it inhibits aggregation. J. Phys. Chem. B 2010, 114, 13426–13438, doi:10.1021/jp108399g.
[130]
Woods, A.S. The mighty arginine, the stable quaternary amines, the powerful aromatics, and the aggressive phosphate: Their role in the noncovalent minuet. J. Proteome Res. 2004, 3, 478–484, doi:10.1021/pr034091l.
[131]
Flocco, M.M.; Mowbray, S.L. Planar stacking interactions of arginine and aromatic side-chains in proteins. J. Mol. Biol. 1994, 235, 709–717, doi:10.1006/jmbi.1994.1022.
[132]
Gallivan, J.P.; Dougherty, D.A. Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. USA 1999, 96, 9459–9464, doi:10.1073/pnas.96.17.9459.
[133]
Crowley, P.B.; Golovin, A. Cation-pi interactions in protein-protein interfaces. Proteins 2005, 59, 231–239, doi:10.1002/prot.20417.
Nakakido, M.; Tanaka, Y.; Mitsuhori, M.; Kudou, M.; Ejima, D.; Arakawa, T.; Tsumoto, K. Structure-based analysis reveals hydration changes induced by arginine hydrochloride. Biphys. Chem. 2008, 137, 105–109, doi:10.1016/j.bpc.2008.07.009.
[136]
Baynes, B.M.; Wang, D.I.; Trout, B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 2005, 44, 4919–4925.
[137]
Arakawa, T.; Tsumoto, K. The effects of arginine on refolding aggregated proteins: Not facilitate refolding, but suppress aggregation. Biochem. Biophys. Res. Commun. 2003, 304, 148–152, doi:10.1016/S0006-291X(03)00578-3.
[138]
Shiraki, K.; Kudou, M.; Fujiwara, S.; Imanaka, T.; Takagi, M. Biophysical effect of amino acids on the prevention of protein aggregation. J. Biochem. 2002, 132, 591–595, doi:10.1093/oxfordjournals.jbchem.a003261.
